Severe adenomyosis and CA125
article
OA: closed
CC0
⤵ 29 in-corpus citations
AI-generated summary
Severe adenomyosis can cause significantly elevated CA125 levels, correlating with uterine volume, whereas fibroids do not raise CA125.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
A total of 50 women having uterine enlargement of > 12 weeks' size due to severe adenomyosis with raised CA125, were carefully studied and compared with other cases. The greater the enlargement of the uterus over 240 cm(3) volume or 12 weeks' uterine size due to severe adenomyosis, the greater was the rise of CA125 levels and these were disturbingly high in some cases. However, similarly enlarged uteri due to fibroids did not show a rise in CA125 levels above normal. Raised CA125 thus need not instil anxiety, when the clinical findings are benign.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (10)
- CA 125 in Benign Gynecological Conditions via openalex
- [Clinical analysis of benign pelvic mass with high serum levels of CA(125)]. via openalex
- The CA 125 tumour-associated antigen: a review of the literature via openalex
- W2052507008 via openalex
- W2091027561 via openalex
- W2092728914 via openalex
- W2283760758 via openalex
- W2587248541 via openalex
- W2011191764 via openalex
- W2024905617 via openalex
Cited by (30)
- The inconsistent pathogenesis of endometriosis and adenomyosis: insights from endometrial metabolome and microbiome 2025
- Magnetic resonance imaging-based Classification criteria combined with Serum CA125 for dysmenorrhea before focused ultrasound ablation surgery in adenomyosis 2024
- Changes of serum CA125 and PGE2 before and after high-intensity focused ultrasound combined with GnRH-a in treatment of patients with adenomyosis 2024
- Stroke in Patients With Common Noncancerous Gynecologic Diseases: A Multicenter Study in Japan 2023
- Serum CA125 as a biomarker for dysmenorrhea in adenomyosis 2023
- Transabdominal and transvaginal egg retrieval guided by a vaginal ultrasound probe in an adenomyosis patient: a case report 2023
- Magnetic Resonance Imaging-guided Focused Ultrasound Surgery in a Swine Adenomyosis Model 2023
- Hypercoagulability in women with adenomyosis who experience heavy menstrual bleeding 2023
- The Role of Platelets in the Pathogenesis and Pathophysiology of Adenomyosis 2023
- 5-Hydroxymethylcytosine profiles in circulating cell-free DNA serve as potential biomarkers for diagnosis and classification of adenomyosis 2023
- Preoperative CA125 as a risk factor for symptom recurrence of adenomyosis after ultrasound-guided high-intensity focused ultrasound ablation surgery 2022
- Maintenance dienogest therapy following adjuvant gonadotropin-releasing hormone agonist treatment after uterus-sparing surgery in adenomyosis: A retrospective cohort study 2022
- HLA-G is highly expressed in the serum of patients with adenomyosis 2022
- Utilization of Pelvic Ultrasonography and CA125 Level to Diagnose Uterine Myoma and Adenomyosis 2022
- Relationship between the serum cancer antigen 125 level and the weight of surgically enucleated adenomyosis 2022
- Maintenance dienogest therapy following adjuvant gonadotropin-releasing hormone agonist treatment after uterus-sparing surgery in adenomyosis: A retrospective cohort study 2022
- Adenomyosis-Associated Ischemic Stroke: Pathophysiology, Detection and Management 2022
- Immunometabolic profiling of cervicovaginal lavages identifies key signatures associated with adenomyosis 2022
- Systemic thromboembolism including multiple cerebral infarctions with middle cerebral artery occlusion caused by the progression of adenomyosis with benign gynecological tumor: a case report 2021
- Serum levels of cancer antigen 125 before hormone replacement therapy are not associated with clinical outcome of frozen embryo transfer in women with adenomyosis 2021
- Ultrasound-guided transvaginal radiofrequency ablation combined with levonorgestrel-releasing intrauterine system for symptomatic uterine adenomyosis treatment 2021
- Severe adenomyosis with unexpectedly high CA-125: report of a rare case 2020
- Serum prolactin and CA 125 levels in uterine adenomyosis 2020
- Evaluation of adenomyosis after gonadotrophin-releasing hormone agonist therapy using ultrasound post-processing imaging: a pilot study 2020
- Combined therapeutic effects of HIFU, GnRH-a and LNG-IUS for the treatment of severe adenomyosis 2019
- Serum Levels of Cancer Antigen 125 before Hormone Replacement Therapy are not Associated with the Clinical Outcome of Frozen Embryo Transfer Cycles among Women with Adenomyosis 2019
- Drug therapy for adenomyosis: a prospective, nonrandomized, parallel-controlled study 2018
- Decreased Endometrial Expression of Leukemia Inhibitory Factor Receptor Disrupts the STAT3 Signaling in Adenomyosis During the Implantation Window 2016
- Ultrasound-guided percutaneous microwave ablation for adenomyosis: efficacy of treatment and effect on ovarian function 2015
- Usefulness of CA125 in the differential diagnosis of uterine adenomyosis and myoma 2014
Source provenance
- europepmc
- last seen: 2026-08-18T06:10:16.649438+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:18:40.923139+00:00
- unpaywall
- last seen: 2026-08-18T06:27:49.008893+00:00
License: CC0
· commercial use OK